Mixed Martial Arts Group Azioni (AMEX: MMA)

Ultime notizie per Mixed Martial Arts Group (AMEX:MMA) Azioni

Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.

Mixed Martial Arts Group Limited Ordinary Shares

Mixed Martial Arts Group Ltd

MEMSCAP SA ORD by Memscap S.A.

META MATERIALS INC by Meta Materials Inc.

Meta Materials Inc

iShares Trust iShares Large Cap Max Buffer Mar ETF

MSM MALAYSIA HOLDINGS BHD by MSM Malaysia Holdings BHD

MSM Malaysia Holdings Bhd

In the preceding three months, 5 analysts have released ratings for Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $161.0, a high estimate of $177.00, and a low estimate of $137.00. This current average represents a 7.11% decrease from the previous average price target of $173.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722121_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Tenet Healthcare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Ha &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $137.00&#x7C;$153.00 &#x7C; 
&#x7C;Jason Cassorla &#x7C;Guggenheim &#x7C;Announces &#x7C;Buy &#x7C; $165.00&#x7C;- &#x7C; 
&#x7C;Craig Hettenbach &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $165.00&#x7C;- &#x7C; 
&#x7C;Sarah James &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $177.00&#x7C;$177.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $161.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tenet Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Tenet Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Unveiling the Story Behind Tenet Healthcare</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining Tenet Healthcare's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -5.71% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.95%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.16.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Tenet Healthcare Stock: Analyst Perspectives (5 Ratings)

News

Contracts

TTEK

Tetra Tech Wins $8M Contract To Provide Engineering Design And Technical Services For Wastewater Treatment Modernization Program

During the last three months, 16 analysts shared their evaluations of Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.44, a high estimate of $185.00, and a low estimate of $137.00. Observing a downward trend, the current average is 3.59% lower than the prior average price target of $171.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722112_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Announces &#x7C;Buy &#x7C; $138.00&#x7C;- &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $137.00&#x7C;$138.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $137.00&#x7C;$154.00 &#x7C; 
&#x7C;Anupam Rama &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $184.00&#x7C;$183.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $150.00&#x7C;$185.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $185.00&#x7C;$185.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $185.00&#x7C;$185.00 &#x7C; 
&#x7C;Yatin Suneja &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $163.00&#x7C;$165.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $185.00&#x7C;$190.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $148.00&#x7C;$154.00 &#x7C; 
&#x7C;Laura Chico &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $147.00&#x7C;$157.00 &#x7C; 
&#x7C;Sumant Kulkarni &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $163.00&#x7C;$172.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $185.00&#x7C;$190.00 &#x7C; 
&#x7C;Tazeen Ahmad &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $179.00&#x7C;$184.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $185.00&#x7C;$170.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $176.00&#x7C;$162.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Neurocrine Biosciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>About Neurocrine Biosciences</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Understanding the Numbers: Neurocrine Biosciences's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Neurocrine Biosciences showcased positive performance, achieving a revenue growth rate of 21.84% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 16.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 3.88%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases efficient use of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NBIX

What 16 Analyst Ratings Have To Say About Neurocrine Biosciences

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated TE Connectivity and provided 12-month price targets. The average target is $159.44, accompanied by a high estimate of $170.00 and a low estimate of $142.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.21%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722104_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of TE Connectivity by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $147.00&#x7C;$150.00 &#x7C; 
&#x7C;Asiya Merchant &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $142.00&#x7C;$165.00 &#x7C; 
&#x7C;Mark Delaney &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $170.00&#x7C;$190.00 &#x7C; 
&#x7C;Chris Snyder &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $155.00&#x7C;$188.00 &#x7C; 
&#x7C;William Stein &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $163.00&#x7C;$165.00 &#x7C; 
&#x7C;Colin Langan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $155.00&#x7C;$151.00 &#x7C; 
&#x7C;Wamsi Mohan &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $170.00&#x7C;$167.00 &#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $168.00&#x7C;$162.00 &#x7C; 
&#x7C;Asiya Merchant &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $165.00&#x7C;$160.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TE Connectivity. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TE Connectivity compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of TE Connectivity's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TE Connectivity's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on TE Connectivity analyst ratings.</a>
<h2>Delving into TE Connectivity's Background</h2>
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
<h3>TE Connectivity: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: TE Connectivity's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 0.13%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: TE Connectivity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): TE Connectivity's ROA excels beyond industry benchmarks, reaching 2.33%. This signifies efficient management of assets and strong financial health.
Debt Management: TE Connectivity's debt-to-equity ratio is below the industry average at 0.34, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Assess TE Connectivity: What You Need To Know

Mizuho analyst Siti Panigrahi maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Outperform and lowers the price target from $165 to $125.

Price Target

TWLO

Mizuho Maintains Outperform on Twilio, Lowers Price Target to $125

Across the recent three months, 14 analysts have shared their insights on NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $56.57, a high estimate of $66.00, and a low estimate of $48.00. This current average has increased by 8.0% from the previous average price target of $52.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722095_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of NEXTracker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;-------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ben Kallo &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $48.00&#x7C;$59.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $58.00&#x7C;$60.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Announces &#x7C;Outperform &#x7C; $55.00&#x7C;- &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $56.00&#x7C;$46.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Raises &#x7C;Market Perform &#x7C; $50.00&#x7C;$48.00 &#x7C; 
&#x7C;Brian Lee &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $61.00&#x7C;$54.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $62.00&#x7C;$50.00 &#x7C; 
&#x7C;Biju Perincheril &#x7C;Susquehanna &#x7C;Raises &#x7C;Positive &#x7C; $54.00&#x7C;$50.00 &#x7C; 
&#x7C;Jon Windham &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $66.00&#x7C;$60.00 &#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $50.00&#x7C;$47.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $56.00&#x7C;$54.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $61.00&#x7C;$58.00 &#x7C; 
&#x7C;Gus Richard &#x7C;Northland Capital Markets&#x7C;Raises &#x7C;Outperform &#x7C; $55.00&#x7C;$48.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $60.00&#x7C;$47.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NEXTracker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NEXTracker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NEXTracker's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NXT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NEXTracker analyst ratings.</a>
<h2>Unveiling the Story Behind NEXTracker</h2>
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
<h3>Unraveling the Financial Story of NEXTracker</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: NEXTracker's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -4.37%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: NEXTracker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): NEXTracker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.63% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.01%, the company showcases effective utilization of assets.
Debt Management: NEXTracker's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 14 Analysts Discuss NEXTracker Stock

14 analysts have shared their evaluations of Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.57, along with a high estimate of $95.00 and a low estimate of $70.00. A decline of 13.37% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722086_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Sempra's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $75.00&#x7C;$77.00 &#x7C; 
&#x7C;Ryan Levine &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $70.00&#x7C;$93.00 &#x7C; 
&#x7C;Sarah Akers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $85.00&#x7C;$88.00 &#x7C; 
&#x7C;David Arcaro &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $86.00&#x7C;$85.00 &#x7C; 
&#x7C;James Thalacker &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $78.00&#x7C;$92.00 &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $77.00&#x7C;$96.00 &#x7C; 
&#x7C;Nicholas Campanella &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $72.00&#x7C;$95.00 &#x7C; 
&#x7C;Carly Davenport &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $76.00&#x7C;$99.00 &#x7C; 
&#x7C;Anthony Crowdell &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $76.00&#x7C;$92.00 &#x7C; 
&#x7C;Shahriar Pourreza &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $87.00&#x7C;$95.00 &#x7C; 
&#x7C;David Arcaro &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $85.00&#x7C;$100.00 &#x7C; 
&#x7C;Daniel Ford &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $78.00&#x7C;$95.00 &#x7C; 
&#x7C;Sarah Akers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $88.00&#x7C;$96.00 &#x7C; 
&#x7C;Eric Beaumont &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $95.00&#x7C;$99.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sempra. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sempra compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sempra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sempra's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sempra analyst ratings.</a>
<h2>Discovering Sempra: A Closer Look</h2>
Sempra Energy serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. SoCalGas and San Diego Gas &amp; Electric distribute gas to more than 20 million customers, while Oncor serves more than 10 million Texas customers. Sempra Infrastructure partners, of which Sempra holds a controlling ownership, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.
<h3>Key Indicators: Sempra's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Sempra showcased positive performance, achieving a revenue growth rate of 7.65% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: Sempra's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sempra's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.25%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.7%, the company showcases effective utilization of assets.
Debt Management: Sempra's debt-to-equity ratio is below the industry average at 1.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Sempra's Future

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on The Interpublic Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $34.25, along with a high estimate of $39.00 and a low estimate of $27.00. Surpassing the previous average price target of $31.00, the current average has increased by 10.48%.
<img src="https://www.benzinga.com/files/images/story/2025/1744722078_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive The Interpublic Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jason Bazinet &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $35.00&#x7C;- &#x7C; 
&#x7C;Adam Berlin &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $27.00&#x7C;$29.00 &#x7C; 
&#x7C;David Karnovsky &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $39.00&#x7C;$32.00 &#x7C; 
&#x7C;Julien Roch &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $36.00&#x7C;$32.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to The Interpublic Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of The Interpublic Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for The Interpublic Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into The Interpublic Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IPG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on The Interpublic Group analyst ratings.</a>
<h2>Get to Know The Interpublic Group Better</h2>
Interpublic Group is among the world's largest advertising holding companies based on annual revenue. It provides traditional advertising services along with digital and other services such as public relations through various acquisitions. IPG has made these services available in over 100 countries. The company generates about 65% of revenue in the US and 17% in the UK and Europe. IPG agreed to merge with Omnicom in December 2024, pending regulatory approval.
<h3>A Deep Dive into The Interpublic Group's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: The Interpublic Group's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -5.5%. This indicates a decrease in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The Interpublic Group's net margin is impressive, surpassing industry averages. With a net margin of 12.06%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The Interpublic Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The Interpublic Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.95%, the company showcases efficient use of assets and strong financial health.
Debt Management: The Interpublic Group's debt-to-equity ratio is below the industry average. With a ratio of 1.12, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On The Interpublic Group Through 4 Analysts

Biotech

General

LYEL

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation For LYL314 In Treatment Of Relapsed And/Or Refractory Large B-Cell Lymphoma

RECT

Rectitude Holdings Awarded First Sub-Contract From China Construction Development; Rectitude Will Supply Clean Power To Tower Cranes, Passenger Hoists, And Other Construction Equipment Across Projects Throughout Singapore Through April 2026.

Barclays analyst Dan Levy maintains Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) with a Overweight and lowers the price target from $23 to $17.

Barclays Maintains Overweight on Dana, Lowers Price Target to $17

Cava Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) short percent of float has risen 16.91% since its last report. The company recently reported that it has 10.94 million shares sold short, which is 14.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cava Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744722030_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cava Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cava Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cava Group's peer group average for short interest as a percentage of float is 10.11%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CAVA

Peering Into Cava Group's Recent Short Interest

Mizuho analyst Siti Panigrahi maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Outperform and lowers the price target from $650 to $600.

SNPS

Mizuho Maintains Outperform on Synopsys, Lowers Price Target to $600

Selective Insurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NYSE">SIGI</a>) short percent of float has risen 11.19% since its last report. The company recently reported that it has 1.43 million shares sold short, which is 3.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Selective Insurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744722024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Selective Insurance Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Selective Insurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Selective Insurance Gr's peer group average for short interest as a percentage of float is 2.32%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SIGI

Looking Into Selective Insurance Gr's Recent Short Interest

Curtiss-Wright's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) short percent of float has fallen 13.7% since its last report. The company recently reported that it has 422 thousand shares sold short, which is 1.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Curtiss-Wright Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744722018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Curtiss-Wright has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Curtiss-Wright's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Curtiss-Wright's peer group average for short interest as a percentage of float is 4.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Curtiss-Wright?

SCLXW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is acting like an asset eager to climb higher if <a href="https://www.benzinga.com/25/04/44730016/bitcoin-will-decouple-with-stocks-in-case-of-a-tariff-fueled-recession-says-analyst-lower-interest-rates-and-massive-money-printing">macroeconomic obstacles were to ease</a>, according to Matt Hougan, Chief Investment Officer at Bitwise Asset Management.
What Happened: Despite significant market turbulence, Bitcoin has demonstrated resilience, trading flat over the past month amid global economic challenges, signaling a maturing asset increasingly viewed as a hedge against macro uncertainties.
Hougan's <a href="https://experts.bitwiseinvestments.com/cio-memos/bitcoins-remarkable-resilience">analysis</a> on Tuesday highlights Bitcoin's stability, noting that it traded at $84,379 at the time of publishing his analysis, nearly unchanged from $84,317 a month prior, a mere 0.07% return over 30 days.
This steadiness comes amid major events, including the U.S. establishing a <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44491124/strategic-bitcoin-reserve-eliminates-last-threat-says-bitwises-matt-hougan">Bitcoin strategic reserve</a> and President Donald Trump's <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44794011/bitcoin-reclaims-momentum-as-100k-calls-resurface-and-tariff-relief-lifts-market-mood">global tariffs</a>.
"Bitcoin is acting like an asset that wants to go higher, if only macro obstacles would get out of the way," Hougan wrote, emphasizing its potential for growth once external pressures subside. 
He expressed frustration at the market's lack of movement, stating, "When I think about all the time, energy and angst I've spent studying the market over the past 30 days, it makes me want to cry."
The report contrasts Bitcoin's performance with historical downturns, showing a shift in its behavior. 
Since February 19, the U.S. equity market, as measured by the S&amp;P 500, has fallen 12.0%, while Bitcoin declined 12.4% over the same period, a stark improvement from past corrections.
In 2022, the S&amp;P 500 dropped 24.5%, but Bitcoin plummeted 58.3%. 
Similarly, during the 2020 COVID-19 market crash, equities fell 33.8%, and Bitcoin dropped 38.1%. In 2018, amid a U.S.-China trade war, the S&amp;P 500 slid 19.36%, while Bitcoin fell 37.22%. 
"Since bitcoin crossed the $1 mark in 2011, it has never outperformed the stock market during a full-on market correction," but he believes this time could be different, given Bitcoin's relative stability, Hougan noted.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44733933/stablecoins-are-doing-for-money-what-whatsapp-did-for-messaging-crypto-venture-capitalist-says">Stablecoins Are Doing For Money What WhatsApp Did For Messaging, Crypto Venture Capitalist Says</a>
Why It Matters: Hougan attributes Bitcoin's resilience to its growing maturity as a macro asset, driven by dual forces: its role as a risk asset with high volatility and its emerging status as a hedge asset akin to gold.
He explained that early in Bitcoin's history, its risk asset nature led to sharp declines during risk-off periods, but recent trends show a shift. 
With corporations, institutions and governments, including the U.S., adopting Bitcoin as a strategic reserve, its hedge asset narrative is strengthening.
This has resulted in a lower beta to equities during downturns, as investors increasingly treat it as "digital gold." 
Hougan acknowledged critics who argue <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44771388/why-is-gold-outperforming-bitcoin">Bitcoin hasn't outperformed gold</a> during this pullback, but he remains optimistic, asserting, "The world is unraveling, and bitcoin is trading above $80,000."
The report also reflects on Bitcoin's evolving investor base, noting that its current strength is a sign of broader acceptance and a more stable market presence, even as macro challenges like tariffs and equity market corrections persist. 
This resilience underscores Bitcoin's potential to become a mainstream financial asset, balancing its risk and hedge characteristics in a turbulent global economy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44731819/why-the-bitcoin-bull-market-is-back-on-at-93000-glassnode">Why The Bitcoin Bull Market Is Back On At $93,000: Glassnode</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Poised To Rise If Macro Obstacles Clear, Bitwise's Matt Hougan Says

Mizuho analyst Siti Panigrahi maintains Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) with a Neutral and lowers the price target from $110 to $85.

SHOP

Mizuho Maintains Neutral on Shopify, Lowers Price Target to $85

Barclays analyst Dan Levy maintains BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) with a Overweight and lowers the price target from $42 to $35.

Barclays Maintains Overweight on BorgWarner, Lowers Price Target to $35

WIIM

TNMG

TNL Mediagene shares are trading higher after the company announced a strategic partnership with Taiwan's PChome Online to launch a content commercial operation to impact the retail media landscape in the region.

Press Releases

BJJLink Fuels MMA.inc's Vision to Transform Mixedmartialarts.com into the Global Epicenter for Martial Arts targeting an $18 billion industry

Mixed Martial Arts Group Limited Publishes Annual Report and Form 20-F for Fiscal Year 2024.

MMA.inc Co-Founder John Kavanagh and Investor Conor McGregor Join President Trump's Inauguration as MMA Takes Center Stage

MMA.inc Acquisition of BJJLink Helps Fuel +40% YOY* Revenue Growth On The Platform As It Targets 44,000 Gyms In An $18.6bn Martial Arts Industry in the US

MMA.inc on Track to Achieve US$0.75 Million1 in Warrior Training Program Gross Sales for the March 25 Quarter, Driven by Record-Breaking 200% YoY Growth2

Mixed Martial Arts (MMA) Market is Substantially Growing, Morphing into a Billion Dollar Opportunity

MMA.inc Unveils Fully Integrated Community and Commerce Platform for the $18.6 Billion Martial Arts Industry

MMA.INC to Expand Reach Across 1,000+ Gyms Coaches and Participants in New Partnership with New Zealand Brazilian Jiu-Jitsu Federation

MMA.INC Expands Further into Latin America with BJJLink Capitalizing on Growth of Brazilian Jiu-Jitsu: $15 Million Annual Revenue Opportunity*

Mixed Martial Arts Group Limited Secures $2 Million Non-Dilutive Financing

PTON

SPHR

Allurion Technologies

The Beachbody Company, Inc. Class A Common Stock

Beachbody Co

Carriage Servs

E-Home Household Service Holdings Limited - Ordinary shares

E-Home Household Service

European Wax Center, Inc. - Class A Common Stock

European Wax Center

Frontdoor

H&R Block

Mister Car Wash

Mixed Martial Arts Group

MEDIROM Healthcare Technologies Inc. - American Depositary Share

MEDIROM Healthcare Techs

OneSpaWorld Holdings Limited - Common Shares

OneSpaWorld Hldgs

Wag Group

Regis

Service Corporation International Common Stock

Service Corp Intl

SunCar Technology Group Inc. - Ordinary Shares

SunCar Tech Gr

WW International

XWELL

YSX Tech. Co., Ltd - Class A Ordinary Shares

Comments

Mixed Martial Arts Group

Notizie

Ultime notizie per Mixed Martial Arts Group (AMEX:MMA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO